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Background: Increasing evidence suggests vascular risk factors (VRF) play a role in the pathogenesis of Alzheimer’s
disease (AD). Epidemiological studies have found associations between VRF and risk of AD. Treating VRF in patients
with AD offers a potential treatment option but ineffective treatments should be avoided in this group who are
frequently on multiple medications and in whom compliance may be challenging.
Methods: Studies containing information on the treatment of VRF in patients with a diagnosis of AD were
identified using a defined search strategy. Randomised controlled trials and observational studies were included.
Results: The pre-specified search strategy retrieved 11,992 abstract articles, and 25 papers including those identified
on review of reference lists and reviews met the inclusion criteria. Of these, 11 were randomised controlled trials
(RCTs) and 14 observational studies. Observational studies suggested that a VRF package and treatment of
hypertension and statin therapy may be associated with improved outcome but these studies suffered from
potential bias. The few RCTs performed were mostly small with short duration follow-up, and do not provide clear
evidence either way.
Conclusions: Observational data raises the possibility that treating VRF could alter the rate of decline in AD.
However RCT data are not yet available to support this hypothesis and to alter clinical practice. RCTs in larger
numbers of individuals with longer follow-up, ideally in the early stages of AD, are required to address this
potentially important treatment question.
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Dementia is a common disorder with major medical,
economic and societal costs. The most frequent cause of
dementia is Alzheimer’s disease (AD). Key neuropatho-
logical hallmarks of the AD brain are diffuse and neur-
itic extracellular amyloid plaques - often surrounded by
dystrophic neurites - and intracellular neurofibrillary
tangles. Although the aetiological mechanisms under-
lying these neuropathological changes remain unclear,
the disease is thought to be multifactorial, resulting from
complex interactions between genetic, lifestyle and* Correspondence: hsm32@medschl.cam.ac.uk
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unless otherwise stated.environmental factors [1]. By 2050 it is estimated that
the number of patients with AD worldwide will quadru-
ple from the current number of 36 million [2].
Although AD is thought to be primarily a neurodegen-
erative disease, several experimental and clinical observa-
tions have suggested that vascular factors may play a role
in disease pathogenesis and progression [3-5]. Prospective
cohort studies have reported associations between vascu-
lar risk factors (VRF) and dementia including hyperten-
sion [6] and diabetes mellitus (DM) [7]. Case-control
studies have linked a wide range of VRF with disease risk,
including hypertension, DM, high cholesterol, atrial fibril-
lation, smoking, obesity and low physical activity.
Not only have VRF been associated with disease risk,
but it has also been suggested that their presenceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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control of VRF could have an impact on disease progres-
sion in the individual patient with AD, and may offer a
useful secondary prevention treatment strategy [5]. Fur-
thermore, it has been suggested that some drugs used to
treat VRF, such as statins, may have specific pleotrophic
protective effects in AD.
Before implementing the widespread treatment of VRF
as part of routine clinical care in AD, it is important to
show that their treatment really does reduce disease pro-
gression and impact on quality of life. To assess this we
performed a systematic review to determine whether
treatment of VRF is associated with improved clinical
outcome in patients with already diagnosed AD. We in-
cluded both randomised controlled trials (RCTs) and ob-
servational studies.
Methods
Studies containing information on the treatment of VRF
in patients with a diagnosis of AD were identified using
a defined search strategy. RCTs and observational stud-
ies were included.
Pre-specified search strategy
PubMed, MEDLINE, Embase, CENTRAL (Cochrane Li-
brary), DARE (Database of Abstracts of Reviews of Ef-
fects) and BIOSIS databases (conference abstract or
proceedings) were searched between 1 January 1966 and
22 March 2014.
Search terms were (dementia OR "Alzheimer's Disease"
OR Alzheimer OR "demented patients" OR "cognitive
decline progression" OR "post-dementia cognitive change"
OR "complications in dementia") AND (vascular risk fac-
tor OR predictors OR hypertension OR diabetes mellitus
OR diabetes OR smoking OR hyperlipidaemia OR hyper-
cholesterolaemia OR cholesterol OR "alcohol intake" OR
overweight OR obesity) AND (treatment OR therapy
OR control OR contribution OR antihypertensives OR
hypoglycemic agents OR insulin treatment OR "smoking
cessation" OR "alcohol intake reduction" OR "hypolipid-
emic agents" OR statins OR diet OR "weight loss" OR
exercise OR "physical activity").
The search was limited to articles on humans, in English
and Italian languages, and full papers. Abstracts were
reviewed and articles potentially meeting inclusion cri-
teria identified. References lists and reviews were hand
searched. To exclude duplicate papers, Reference Man-
ager 12 was used.
Articles were included if they fulfilled the following
criteria: five patients or more; AD dementia (according
to diagnostic criteria); VRFs (hypertension, DM, hyper-
lipidaemia, smoking, overweight and no exercise) de-
fined according to reported criteria; AD progression
with outcome measures (for example, Mini Mental ScoreExamination (MMSE) for cognition, Activities of Daily
Living (ADL) and Modified Rankin Scale for disability);
studies with a mixture of dementia types where it was
possible to separate out the data on the AD patients;
studies with a mixture of patients with AD and of mild
cognitive impairment (MCI) where it was possible to
separate the two groups.
Studies that dealt exclusively with laboratory or neuro-
imaging surrogate markers (for example, white matter
hyperintensities on magnetic resonance imaging, cere-
bral blood flow measurements, cerebrospinal fluid
markers or neuropathology) were not included.
Data extraction and management
All studies meeting the inclusion criteria were independ-
ently assessed by two authors. In the event of disagree-
ment or divergent analysis, a consensus was achieved by
discussion between authors. If eligible data were avail-
able for a subset of study patients, the subset fitting the
inclusion criteria was included. For duplicate data
among studies, the article with the largest number of pa-
tients and/or longest follow-up was included.
Extracted data from articles meeting inclusion criteria
were inserted into a standard proforma. The following
information was collected: type of study (prospective,
observational, RCT and retrospective studies); number
of patients; recruitment of consecutive subjects; screen-
ing criteria for AD diagnosis; type of intervention or
drug for each VRF; outcome measures instrument;
follow-up or treatment duration; impact of vascular con-
ditions on cognitive decline or progression of dementia;
concomitant use of drugs for dementia; complications,
institutionalisation and mortality.
Quality of data, including the presence of possible bias,
was recorded and inserted into a standard proforma.
Results
The search strategy retrieved 11,992 abstract articles
from PubMed (5,170), MEDLINE (1,917), Embase
(3,621), CENTRAL (1,217), DARE (50), and BIOSIS (17).
Abstract screening identified 135 studies and, after read-
ing full-text papers and identifying additional papers
from reviews and reference lists, 25 of these studies met
all inclusion criteria. Among these, 11 were RCTs and
14 were observational studies. Results are presented sep-
arately for these two study types. Observational studies
were only included if they reported treatment of VRFs;
studies in which the relationship between the presence
of VRF, rather than their treatment, and AD progression
were not included.
Randomised controlled trials
Table 1 summarises the main features of the RCTs. Studies
are hereafter reviewed according to risk factor treatment.
Table 1 Randomised controlled trials that assessed the treatment of vascular risk factors in patients with a diagnosis of Alzheimer’s disease
Vascular risk factors First author, reference Population Diagnosis criteria Treatment arm (n, drug/daily) Control arm (n) Duration of
follow-up
(months)
Measurement instrument
Vascular care package Richard et al. 2009 [9] 123 AD (with
co-existent
cerebrovascular
disease)
NINCDS-ADRDA 58 vascular care (aspirin,
advice on smoking cessation,
weight loss and exercise)
65 placebo 24 IDDD, MMSE, RMBPC,
measures of poor
outcome
Hypertension Ohrui et al. 2004 [10] 162 AD NINCDS-ADRDA 51 brain-penetrating ACE-I 53 non-brain penetrating
inhibitor versus 58
calcium-channel blocker
12 MMSE
Kume et al. 2012 [11] 20 AD NINCDS-ADRDA,
DSM IV
10 telmisartan (40 to 80 mg) 10 amlodipine
(5 to 10 mg)
6 MMSE, ADAS-JCog,
WMS-R
Diabetes mellitus Watson et al. 2005 [20] 21 mild AD NINCDS-ADRDA 14 rosiglitazone (4 mg) 7 placebo 4, 6 Buschke Selective
Reminding Test, Story
Recall, SCWI, TMT,
category fluency
Hanyu et al. 2009 [21] 26 AD NINCDS-ADRDA 12 pioglitazone (15, 30 mg) 14 placebo 6 MMSE, IDDD, RMBPC
Sato et al. 2011 [22] 42 mild AD NINCDS-ADRDA 21 pioglitazone (15 to 30 mg) 21 placebo 6 MMSE, ADAS-JCog,
WMS-R, FAB
Risner et al. 2006 [23] 511 mild-to
moderate
probable AD
NINCDS-ADRDA 389 rosiglitazone (2, 4 or 8 mg) 122 placebo 6 ADAS-Cog, CIBIC+
Gold et al. 2010 [24] 581 AD NINCDS-ADRDA 331 rosiglitazone (2 or 8 mg) 166 placebo 6 ADAS-Cog, CIBIC+
Hypercholesterolaemia Sparks et al. 2005 [30] 67 AD NINCDS-ADRDA 32 atorvastatin (80 mg) 31 placebo 12 MMSE, ADAS-Cog, CGIC
Simons et al. 2002 [31] 44 probable AD NINCDS-ADRDA 24 simvastatin (80 mg) 20 placebo 6.5 MMSE, ADAS-Cog
Feldman et al. 2010 [33] 640 AD NINCDS-ADRDA 297 atorvastatin (80 mg) 317 placebo 18 MMSE, ADAS-Cog,
ADCS-CGIC NPI,
CDR-SB, ADFACS
ACE-I, angiotensin converting enzyme inhibitors; AD, Alzheimer’s disease; ADAS-Cog, Assessment Scale - Cognitive; ADAS-JCog, Assessment Scale - Cognitive Subscale (Japanese version); ADCS-CGIC, Alzheimer’s Disease
Cooperative Study Clinical Global Impression of Change; ADFACS, Alzheimer’s Disease Functional Assessment and Change Scale; CDR-SB, Clinical Dementia Rating - Sum of Boxes; CIBIC+, Clinician’s Interview-Based
Impression of Change Plus Caregiver Input; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; FAB, Frontal Assessment Battery; IDDD, Interview for Deterioration in Daily activities in
Dementia; MMSE, Mini Mental Score Examination; RMBPC, Revised Memory and Behavioural Problems Checklist (Additional file 1); SCWI, Stroop Color-Word Interference; TMT, Trail-Making Test; WMS-R, Wechsler
Memory Scale Revised.
The NINCDS-ADRDA Alzheimer's Criteria: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association.
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One RCT examined the effectiveness of a vascular care
package that included aspirin, folic acid and pyridoxine
drug therapy as well as advice on smoking cessation,
weight loss and exercise [9]. Within this trial, 123 pa-
tients with mild AD with neuroimaging evidence of co-
existent cerebrovascular disease (white matter hyperin-
tensities or infarcts) were randomised and there was a
two-year follow-up. Eleven patients died during follow-
up and 18 dropped out. Significant differences in homo-
cysteine and cholesterol occurred, but there was no
difference, not even a trend, in the primary endpoint of
disability or in secondary endpoints of MMSE or the
Revised Memory and Behavioural Problems Checklist
(Additional file 1) [9].
Hypertension treatment
We found no RCTs comparing antihypertensive treat-
ment with placebo, although we identified two RCTs
that compared the effectiveness of different antihyper-
tensive agents in patients with AD.
One trial examined the hypothesis that brain-
penetrating angiotensin converting enzyme inhibitors
(ACE-I) would slow the rate of cognitive decline in pa-
tients with mild to moderate AD with hypertension [10].
This was on the rationale that certain components of
the renin-angiotensin system (RAS) may have a role in
learning and memory processes. In this trial, 162 patients
were randomly assigned on an open basis to one of three
treatment options: a brain-penetrating ACE-I (perindopril
or captopril), a non-brain penetrating inhibitor (enalapril
or imidapril), or a calcium antagonist (nifedipine or nilva-
dipine). Mean baseline MMSE values were 19.3, 20.7 and
20.5 in the three groups respectively. There was no diffe-
rence in blood pressure between the three groups. The
mean decline in the primary endpoint of the MMSE dur-
ing the one-year follow-up was significantly lower in the
groups treated with a brain-penetrating ACE-I (0.6, stan-
dard error (SE) = 0.1) than those in the other two groups:
4.6 (SE = 0.3) and 4.9 (SE = 0.3) respectively [10].
In a small study looking primarily at cerebral blood
flow, 20 patients with AD were randomised to open
therapy with telmisartan, an angiotensin receptor
blocker (ARB), or amlodipine for six months. Cognition
did not change in the telmisartan group but declined in
the amlodipine group [11].
Diabetes mellitus treatment
The only RCTs of diabetic treatment are of peroxisome
proliferator-activated receptor gamma (PPARγ) agonists,
and have examined whether this particular class of drug
has a protective effect rather than whether tighter dia-
betic control itself improves outcome. PPARγ agonists
increase glucose sensitivity, regulate lipid metabolismand promote mitochondrial biogenesis [12,13]. They also
exhibit robust anti-inflammatory actions via their ability
to suppress NF-κB-dependent gene expression [14,15].
AD is typified by impaired glucose utilization in the
brain and a glial-mediated inflammatory response, sug-
gesting the potential utility of these agents in the treat-
ment of AD [14-16]. Studies in murine models of AD
demonstrated that rosiglitazone lowers amyloid plaque
burden, reduces vascular and plaque-associated inflam-
mation, attenuates loss of synaptic connectivity, and im-
proves memory and cognition [14,17-19]. They have
been tested both in patients with AD and diabetes, and
patients with AD but without diabetes.
A pilot study suggested the PPARγ agonist rosiglitazone
improved cognition in patients with mild-to-moderate AD
[20]. Another small open study in 32 patients with both
mild-to-moderate AD (or amnestic MCI) and diabetes
mellitus not on insulin randomised patients between the
PPARγ agonist pioglitazone or no additional treatment. A
significant decrease in the AD Assessment Scale - Cogni-
tive Subscale Japanese version (ADAS-JCog) and increase
in the Wechsler Memory Scale Revised (WMS-R), but no
change in MMSE, was found in the pioglitazone group
[21]. Another small study in 42 patients with mild AD and
type II DM primarily looked at regional cerebral blood
flow but also included data on cognitive outcome, and
suggested a protective effect of pioglitazone [22]. Patients
were randomly assigned to open treatment with 15 or
30 mg daily pioglitazone in addition to their previous
oral hypoglycaemic treatments. After six months, scores
on the the MMSE, ADAS-JCog and WMS-R logical
memory-I improved significantly in the pioglitazone
group, while the ADAS-JCog worsened significantly in
the control group. Neither group showed any significant
change in the Frontal Assessment Battery and category
fluency [22].
However, larger trials in patients with AD without dia-
betes have not replicated these positive results. A phase
2 trial in 511 non-diabetic patients with mild-to-
moderate AD randomised participants between placebo
or 2, 4 or 8 mg rosiglitazone [23]. There were no statisti-
cally significant differences in the primary endpoints
(ADAS-Cog and Clinician’s Interview-Based Impression
of Change Plus Caregiver Input (CIBIC+)) after 24
weeks’ treatment. Results were also stratified by ApoE
genotype in a subgroup (n = 323); there was a significant
interaction between ApoE epsilon4 allele status and
ADAS-Cog (P = 0.014) with ApoE4-negative individuals
appearing to show an improvement in response to rosi-
glitazone, whereas ApoE epsilon4 allele carriers showed
no improvement and some decline was noted. But this
interaction with ApoE status was not confirmed in a
subsequent study. This double-blind phase 2 trial rando-
mised 581 individuals with mild-to-moderate AD without
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placebo, or donepezil as a positive control [24]. At week
24, there was no significant difference from placebo in
change from baseline in the ADAS-Cog score and CIBIC +
with either rosiglitazone dose in the 50% of individuals
who were ApoE epsilon4-negative, or overall [24].
Statin treatment
Statin (3-hydroxy-3-methylglutaryl-coenzyme A reduc-
tase inhibitors) treatment might act via a general cardio-
vascular protective effect due to cholesterol lowering or
via a more specific effect on AD pathology. Cholesterol
modulates the processing of amyloid precursor protein
(APP)-related Aβ production in vitro and in animal
model studies [25,26]. AD neuropathologic lesions are
demonstrable in patients who have coronary artery dis-
ease and no dementia [27]. Reducing cholesterol through
the use of statins appears to affect the processing of APP
and the production of Aβ. A diet high in cholesterol in-
creased Aβ accumulation and AD-related pathology in
the transgenic mouse model, with relatively little change
in brain cholesterol [28], and feeding a high-cholesterol
diet to rabbits has also produced Aβ deposits in the
hippocampus [29].
A single-centre study randomised 67 patients with
mild-to-moderate AD (MMSE score of 12 TO 28) to ei-
ther atorvastatin or placebo on a double-blind basis for
one year [30]. A significant positive effect on ADAS-Cog
performance occurred after six months of atorvastatin
therapy compared with placebo, although the difference
was not quite significant at one year [30]. Another small
study of 44 patients with probable AD of mild-to-
moderate severity (MMSE score 12 to 26), which was
primarily looking at the effects of stains on cerebrospinal
fluid markers, assessed cognition as a secondary out-
come [31]. Patients were randomised to placebo or sim-
vastatin and the simvastatin group had less decline in
MMSE score during follow-up [31].
A post hoc analysis was conducted on data pooled
from three double-blind, placebo-controlled, clinical tri-
als of galantamine in patients with AD divided into four
treatment groups: statin plus galantamine (n = 42), statin
alone (n = 50), galantamine alone (n = 614), or neither
galantamine nor statin (n = 619) [32]. Galantamine was
associated with a significant beneficial effect on cognitive
status, and although there was no significant benefit
from statins (P = 0.083), there was a trend which led the
authors to suggest further studies were needed [32].
By contrast, a subsequent larger international multi-
centre, double-blind, randomised, parallel-group study
failed to confirm these benefits [33]. The authors exam-
ined the use of atorvastatin in patients without an indi-
cation for statin, that is, no cardiovascular disease and
low-density lipoprotein cholesterol levels on study entrybetween 95 and 195 mg/dL [33]. The 640 participants ran-
domised had mild-to-moderate probable AD (MMSE 13
to 25), were aged 50 to 90 years, and were all taking 10
mg donepezil daily. They were randomised to 80 mg/day
atorvastatin or placebo for 72 weeks. There were no sig-
nificant differences in the co-primary endpoints of ADAS-
Cog score or global function assessed by the Alzheimer’s
Disease Cooperative Study Clinical Global Impression of
Change. The proportion discontinuing treatment was
34.1% in the statin group and 24.5% in the placebo group,
with those discontinuations felt to be related to therapy in
11.5% and 1.5% respectively. The authors suggest a limita-
tion is that statin therapy may be more useful in those pa-
tients with AD patients and co-existing cardiovascular
disease and/or high cholesterol level [33].
Observational studies
A number of observational studies have evaluated whether
the treatment of VRF is associated with a slower progres-
sion of cognitive decline or better outcome in AD patients
(Table 2), although it is notable that for some VRF such as
smoking and obesity we could find no data.
Vascular care package addressing multiple risk factors
One study identified 280 patients from a memory clinic
who had AD with no evidence of cerebrovascular disease
and followed them up for six months [34]. Each VRF
(high blood pressure, dyslipidaemia, DM, smoking) was
considered treated if the patient received a specific
medication. MMSE decline was slower for patients with
all VRF treated compared with no VRF treated. There
was a non-significant trend in patients with only some
VRF treated. Although limited by the small numbers in
each group, analysis of individual VRF found a signifi-
cant effect only for the treatment of dyslipidaemia with
either a statin or a fibrate [34].
In the Dementia Progression Study of the Cache
County Study on Memory, Health and Aging, 216 indi-
viduals with incident AD were followed for a mean of
three years [35]. The Clinical Dementia Rating Sum of
Boxes (CDR-Sum) increased an average of 1.69 points
annually, indicating a steady decline in functioning.
After adjustment for demographic variables and the
baseline presence of cardiovascular conditions, use of
statins (P = 0.03) and beta-blockers (P = 0.04) were asso-
ciated with a slower annual rate of increase in CDR-Sum
of 0.75 and 0.68 points respectively, while diuretic use
was associated with a faster rate of increase in CDR-Sum
(P = 0.01; 0.96 points annually) [35].
Hypertension treatment
A number of studies have examined whether ant-
hypertensive therapy is associated with reduced cogni-
tive decline in AD. Some studies have included only
Table 2 Observational studies that evaluated whether the treatment of vascular risk factors is associated with a slower progression in patients with Alzheimer’s disease
Vascular risk factors Study Population Diagnosis criteria Treatment arm and comparator (if any)
(n, drug/daily)
Duration of
follow-up (months)
Measurement
instrument
Vascular care package Deschaintre et al. 2009 [34] 280 consecutive AD NINCDS-ADRDA, DSM IV 208 treated (119 with some VRF treated and 89
with all VRF treated) versus 72 without treatment
27 MMSE
Rosenberg et al. 2008 [35] 216 AD NINCDS-ADRDA, DSM III R Cardiovascular medication (ACE-I, β-blockers,
calcium ion channel blockers, diuretics, statins,
nitrates, platelet inhibitors or digoxin)
36 CDR-Sum
Hypertension Razay et al. 2009 [36] 141 AD NINCDS-ADRDA,
NINDS-AIREN
Antihypertensive medications 60 CAMCOG
Duron et al. 2009 [37] 321 consecutive AD NINCDS-ADRDA, DSM IV 127 treated with antihypertensive drugs (calcium
channel blockers, β-blockers, ACE-I, diuretics, ARB)
versus 149 not treated
34.1 MMSE
Bellew et al. 2004 [38] 719 mild-to- severe AD NINCDS-ADRDA Antihypertensive drugs 6 MMSE, ADAS-Cog
Li et al. 2010 [39] 12574 AD ICD 9 3,227 treated with lisinopril versus 476 with
ARB versus 8,871 other cardiovascular drugs
48 Admission to
nursing home
12879 AD 3,333 treated with lisinopril versus 491 with
ARB versus 9,055 other cardiovascular drugs
Mortality
Hajjar et al. 2008 [40] 62 AD NINCDS-ADRDA 15 treated with ACE-I versus 47 untreated 6 MMSE, CDT, DO,
IADL, SCB
Soto et al. 2013 [41] 616 mild-to-moderate AD NINCDS-ADRDA 61 treated with ACE-I versus 189 with other
antihypertensive drugs versus 309 without
antihypertensive drugs
48 MMSE
Ellul et al. 2007 [42] 224 probable AD NINCDS-ADRDA 92 treated with antihypertensive drugs (including
20 with ACE-I and 2 with ARB), 12 with statins
and 10 with anti-diabetic drugs
12 GDS
Kehoe et al. 2013 [43] 3905 AD Oxford Medical Information
System or Read codes and
prescriptions
1,323 treated with ACE-I versus 265 ARB
versus 2,315 other antihypertensive drugs
120 Hospitalization
and mortality
Diabetes mellitus Plastino et al. 2010 [44] 104 AD DSM IV 49 oral anti-diabetic drugs versus 55 insulin
oral + anti-diabetic drugs
12 MMSE, CGI
Hypercholesterolaemia Masse et al. 2005 [45] 234 AD NINCDS-ADRDA 129 were dyslipaemic treated with LLAs
(47% with statins) versus 105 untreated
34.8 MMSE
Ellul et al. 2007 [42] 224 probable AD NINCDS-ADRDA 92 treated with antihypertensive drugs (including
20 with ACE-I and 2 with ARB), 12 with statins
and 10 with anti-diabetic drugs
12 GDS
Padala et al. 2012 [48] 12 AD - Statins [atorvastatin (10, 20, 40, 80 mg), simvastatin
(10, 40 mg), fluvastatin (20, 40 mg), pravastatin
(20 mg), rosuvastatin (10 mg), lovastatin (40 mg)]
3 (1.5 discontinuation
and 1.5 re-challenge)
MMSE, CERAD,
ADL, IADL
ACE-I, angiotensin converting enzyme inhibitors; AD, Alzheimer’s disease; ADAS-Cog, AD Assessment Scale-Cognitive; ADL, Activities of Daily Living; ARB, angiotensin receptor blockers; β-blockers, β-blocking anti-adrenergics;
CAMCOG, Cambridge Cognitive Examination; CDR-Sum, Clinical Dementia Rating Sum of Boxes; CDT, Clock Draw Test; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; CGI, Clinical Global Impression; DO, Digit
Ordering; DSM III R, Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revision; GDS, Global Deterioration Scale; IADL, Instrumental Activities of Daily Living; MMSE, Mini Mental Score Examination; SCB, Screen
for Caregiver Burden.
ICD- International Statistical Classification of Diseases and Related Health Problems. Usually just ICD would be used.
NINDS-AIREN National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences.
NINCDS-ADRDA. as previously.
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normotensive individuals [37,38].
In the longitudinal OPTIMA study, among the 141 pa-
tients with AD in whom blood pressure was recorded, the
rate of decline on Cambridge Cognitive Examination
(CAMCOG) scores showed an inverted U-shape de-
pendent on diastolic blood pressure. The use of any anti-
hypertensive medication in those with AD was related to
significantly better CAMCOG scores (P = 0.008) [36].
In a prospectively collected database of 321 patients
with AD and hypertension with a mean follow-up of 34
months, cognitive function was assessed yearly by
MMSE [37]. Fifty-four per cent of patients received at
least one antihypertensive drug while 33% of those pa-
tients without antihypertensive treatment were hyper-
tensive. Medication included different classes of drugs.
MMSE was significantly higher among patients using anti-
hypertensive drugs compared to those without antihyper-
tensive treatment after adjustment for main confounders
(19.0 versus 17.5, P <0.0001 at three years) [37].
A case-control study investigated the association be-
tween hypertension and cognitive decline in 719 patients
diagnosed with AD who had been randomly assigned to
the placebo arm of a clinical trial and followed-up for
six months [38]. Eighty per cent had hypertension at
baseline, defined as a past history, treatment or raised
blood pressure. After controlling for baseline disease se-
verity, patients with AD and hypertension were more
likely to have increased cognitive decline with an odds
ratio of 1.6. Secondary analysis suggested this effect was
confined to younger patients (below 65 years). Treat-
ment with antihypertensive medication appeared to have
no effect on the rate of cognitive decline in those pa-
tients with AD and hypertension [38].
It has been suggested that drugs blocking the RAS,
both ACE-I and ARB, might be particularly effective at
preventing cognitive decline in AD; ARB may have had
beneficial effects on cognition in some studies in pa-
tients without AD [39]. In a small study, 15 patients with
both AD and hypertension treated with ACE-I were
compared with 47 patients, of whom 43% were hyper-
tensive, who were not treated [40]. Over a six-month
follow-up, patients receiving ACE-I had a slower rate of
decline in digit forward and Instrumental Activities of
Daily Living scale, and an improved measure of caregiver
burden after adjusting for other risks factors [40].
A further study evaluated 686 patients with AD, of
whom 75% had hypertension [41]. Sixty-one were con-
tinuous users of ACE-I, 59 used ACE-I intermittently,
189 were users of other antihypertensive drugs, and 309
had never used antihypertensive drugs. The four-year
decline in MMSE was 6.4, 7.9, 8.8 and 10.2 respectively.
In a subgroup analysis, the 118 participants who had
continuously or intermittently used ACE-I had asignificantly lower decline compared with the 498 who
had never used ACE-I (7.5 versus 9.7; P = 0.03) [41].
A study in 224 patients associated a wide variety of
drugs with progression measured as a change in the Glo-
bal Deterioration Scale. About half of the patients were
on heart and antihypertensive drugs. As part of the ana-
lysis they found a protective effect of ACE-I [42].
A large study used the US Veterans database to exam-
ine the hypothesis that inhibition of the RAS might have
a specific effect on dementia and that ARB treatment
might be more effective than ACE-I [39]. The authors
looked at progression of dementia in those with AD at
baseline, with progression defined as death or admission
to a nursing home. Patients on an ARB, on the ACE-I
lisinopril, and on cardiovascular comparators (excluding
an ARB, ACE-I or statin) were compared; the proportion
with hypertension in each group was 93%, 91% and 80%
respectively. Compared with the cardiovascular com-
parator, ARB in patients with pre-existing AD were asso-
ciated with a significantly lower risk of admission to a
nursing home (0.51; 95% confidence interval, 0.36 to
0.72) and death (0.83; 95% confidence interval, 0.71 to
0.97). ARB exhibited a dose-response as well as additive
effects in combination with ACE-I [39].
In the large UK-based General Practice Research data-
base it was hypothesised that the rates of progression to
hospitalisation or death would be lower for patients with
AD treated with an ARB compared to patients on other
antihypertensive drugs through the reduction of angio-
tensin II signalling [43]. In 3,905 patients with AD, nei-
ther mortality or hospitalisation rates with ARB were
different from those in patients treated with other anti-
hypertensive drugs. Unexpectedly, ACE-I were associ-
ated with a significantly higher mortality, but not with
any increase in hospitalisation [43].
Diabetes mellitus treatment
We could find no studies addressing the effect of dia-
betic therapy or control on outcome in AD, but one
looked at possible protective effects of insulin therapy.
Cognitive decline was compared between patients with
mild-to-moderate AD and DM treated with insulin (n =
55) and those on oral hypoglycaemic agents alone (n =
49) [44]. At 12 months, mean MMSE decreased in those
treated with oral hypoglycaemic agents (20.4 ± 4.1 versus
18.2 ± 3.6; P = 0.001), but remained stable in insulin-
treated patients (21.9 ± 5.1 versus 21.2 ± 3.9; P = 1.03).
No analysis of glucose control was performed and there-
fore it is unclear whether this difference related to better
diabetic control or other effects of insulin [44].
Statin treatment
We could find no studies examining the effect of statins
exclusively in patients with AD and hyperlipidaemia but
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treatment in patients with AD in which the diagnosis of
hypercholesterolaemia was not present in all patients.
Interpretation is complex because some studies ad-
dressed both concerns as to whether short-term statin
therapy may impair cognition, whereas others looked at
protective effects over longer periods of follow-up.
A three-year observational study followed 342 patients
with AD (MMSE 21.3 at entry) [45]. Patients were classi-
fied into those with dyslipaemia and treated with lipid-
lowering agents (n = 129; 47% with statins), those who
had untreated hyperlipidaemia (n = 105), and those who
were normolipidaemic (n = 108) [45]. Patients treated
with lipid-lowering agents had a slower decline on the
MMSE (1.5 point/year, P = 0.01) than patients with un-
treated dyslipidaemia (2.4 points/year) and normolipi-
daemic patients (2.6 points/year) [45].
A study in 224 patients associated a wide variety of
drugs with progression in AD. Only 12 (5%) were on sta-
tins, but this group had less decline on the Global De-
terioration Scale [42].
The US Food and Drug Administration has added
safety warnings to statins concerning confusion and
memory loss [46]. Initial evidence of such adverse events
came from case reports describing subjective and revers-
ible worsening of cognition in individuals using statins,
although none of those reports included objective cogni-
tive measures [47]. Also case series are reported in
which patients with MCI or dementia had a significant
improvement in their MMSE score when statins were
discontinued [48]. In 12 patients with AD, the short-
term effects of statin withdrawal were studied in a 12-
week prospective non-blinded study involving a six-week
withdrawal phase and a six-week challenge phase [48]. A
specific aim was to address concerns that statins might
be associated with short-term memory impairment. There
was an improvement in MMSE scores (+1.9 [3.0], P =
0.014) with discontinuation of statins and a decrease in
MMSE scores (−1.9 [2.7], P = 0.007) after re-challenge
[48]. Two prospective studies showed minor declines in
cognition of uncertain significance in adults with hyperlip-
idaemia treated with statins [49,50].
Discussion
How to treat VRF in this patient group is a common
question facing clinicians, and if such treatment does
have an effect on slowing disease progression it could
have a major population impact due to the high preva-
lence of AD. A clear treatment benefit would mandate a
systematic search for cardiovascular risk factors in this
patient group. However, this is a patient group who may
already be on other medications and in whom compli-
ance can be difficult [51-54], and therefore it is import-
ant to avoid giving ineffective treatments. There are noclear guidelines as to optimal management in this area
and therefore we carried out this systematic review.
Although there is substantial evidence that VRF are as-
sociated with an increased risk of AD, few studies have
examined the effect of treatment of VRF, either as a
package or individually, on progression of disease in pa-
tients with established AD.
The majority of studies we found were small. The in-
terpretation is further complicated because a number of
studies tested whether specific classes of drugs that alter
AD pathology in animal models were effective, rather
than testing whether treatment of the specific risk factor
per se altered disease progression.
We found only 11 RCTs addressing this area and of
these two compared different drug classes rather than de-
termining whether treatment of the risk factor itself al-
tered outcome. Sample sizes of thousands with follow-up
of usually two to three years or more have been required
to show effectiveness of risk factor treatment in secondary
prevention of stroke; one might expect that similar sample
sizes and follow-up would be required to determine whe-
ther VRF treatment alters progression in AD. Slightly
more data was available from observational studies but
again these suffered from relatively small sample sizes and
many were retrospective analyses of pre-existing datasets.
One approach is to provide a vascular care package
where all common VRF are treated. Two observational
studies, each in approximately 200 patients with follow-
up of six months and three years respectively, did sug-
gest that such an approach might be associated with de-
layed progression [34,35]. However, such observational
studies suffer from the potential bias that those patients
being treated may be those who are felt to have a better
prognosis and therefore have been given treatment for
VRF. Only one small RCT examined this approach, and
found no treatment effect [9]. Much larger sample sizes
are required to definitely determine whether a package
of VRF treatment will delay disease progression.
Considerable evidence suggests that hypertension is
associated with an increased risk of AD [6], but there is
much less data determining whether treatment of hyper-
tension delays progression in patients with established
disease. Observational data in a total of approximately
1,000 patients suggests that treatment may be associated
with reduced progression. To date, no RCTs have exam-
ined this question.
There has been more interest in whether specific clas-
ses of antihypertensive drugs may have particular bene-
fit. In particular, it has been hypothesised that drugs
blocking the RAS, both ACE-I and ARB, might have spe-
cific benefits in AD. One large study of the US Veterans
database [39] found ARB use appeared to be associated
with improved outcome, and this study and some other
smaller studies have suggested that ACE-I may also be
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has received some support from small RCTs but further
data is required before their routine use in AD can be
recommended.
We found very little data on whether intensive control
of diabetes is associated with reduced progression of AD.
It has been suggested that the PPARγ agonists may have
specific benefits in AD, perhaps by anti-inflammatory ef-
fects. This has led to these drugs, used as treatments in
diabetes, to be tested in RCTs in AD. They have been
given to patients with and without a diagnosis of diabetes.
Although smaller studies suggested benefit, two larger tri-
als in patients with no diabetes have not replicated these
results [23,24].
Statin therapy could potentially reduce AD progression
via its cholesterol-lowering effect and a reduction in vascu-
lar damage. It may have a more specific effect in AD, per-
haps by altering processing of APP and production of Aβ.
A relatively small number of observational studies provide
some support for a benefit treatment effect, as do small
RCTs. However, the only larger RCT performed in this
area, which recruited 640 patients who were treated for 72
weeks, found no beneficial effect of atorvastatin [33].
Taken together, the available observational data raises
the possibility that treating VRF could alter the rate of
decline in AD. However, RCT data is not yet available to
support this hypothesis and to alter clinical practice.
One might expect the magnitude of benefit would be
no greater than that seen in secondary prevention of car-
diovascular disease including stroke. If that is the case,
there needs to be a paradigm shift in clinical trials ad-
dressing this issue. Much larger sample sizes are re-
quired, in the thousands or even tens of thousands as
have been recruited to cardiovascular trials, and the dur-
ation of follow-up needs to be a number of years. Several
cardiovascular trials, such as for statin therapy [55], have
not shown separation between the treatment and pla-
cebo arms until after one year. Because the timescale to
show benefit is likely to be a few years, it may be most
practical to perform trials in patients with early AD.
One potentially attractive option would be to perform
trials using a VRF package including treatment of com-
mon risk factors such as hypertension, DM, hypercholes-
terolaemia and smoking cessation.
Studies need to address a number of other important
potential confounding factors. Population-based studies
have shown that many individuals have a mixed demen-
tia with pathological features of both AD and vascular
disease. One might expect treatment of VRF to have a
more beneficial effect in this group, compared with
‘pure’ AD without vascular changes. Stratification by the
presence or absence of neuroimaging changes such as
leukoaraiosis and lacunar infarction on brain imaging
may prove useful in investigating this area further.Conclusions
Considerable observational evidence has associated VRF
with AD, raising the possibility that treating VRF could
alter the rate of decline in AD. In this systematic review,
we found that although some smaller studies suggest
there may be a treatment effect, studies have been largely
underpowered and do not provide sufficient data to
change clinical practice.
What does a clinician do when faced with a patient
with AD and VRF? One option is to treat all possible
VRF on the assumption it may do good and is unlikely
to do harm. Although superficially attractive, this ap-
proach is not ideal. Prescribing large numbers of inef-
fective drugs has significant disadvantages, in addition to
the cost. A study found that patients with AD are rou-
tinely prescribed at least five drugs, and many are pre-
scribed even more, in an attempt by providers to
optimise disease state control [51]. In this predominantly
elderly group with impaired cognition, compliance is
often poor and the potential for misdosage high. Forty-
one per cent of patients with AD on cardiovascular
drugs were not taking their drugs regularly [52]. Further-
more, although widely used, drugs to treat VRF are not
uncommonly associated with side effects, particularly in
the elderly population most affected by AD, which can
reduce quality of life.
Until the evidence base is stronger, a reasonable option
is to treat VRF intensively if there is evidence of co-
existent cardiovascular disease including both myocar-
dial infarction and cerebrovascular disease. This could
include evidence of cerebrovascular disease on brain im-
aging. But large, adequately powered trials are needed,
ideally in the early stages of AD and in MCI, to deter-
mine whether treating VRF does delay progression in pa-
tients without overt cerebrovascular disease. If these are
positive, this would have a major impact on the way AD
is treated, and mean that protocols to screen patients
with AD to detect and treat cardiovascular risk factors
would need to be established.
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